Antiangiogenic gene therapy of cancer

Recent developments

Anita Tandle, Dan G. Blazer, Steven K. Libutti

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

With the role of angiogenesis in tumor growth and progression firmly established, considerable effort has been directed to antiangiogenic therapy as a new modality to treat human cancers. Antiangiogenic agents have recently received much widespread attention but strategies for their optimal use are still being developed. Gene therapy represents an attractive alternative to recombinant protein administration for several reasons. This review evaluates the potential advantages of gene transfer for antiangiogenic cancer therapy and describes preclinical gene transfer work with endogenous angiogenesis inhibitors demonstrating the feasibility of effectively suppressing and even eradicating tumors in animal models. Additionally, we describe the advantages and disadvantages of currently available gene transfer vectors and update novel developments in this field. In conclusion, gene therapy holds great promise in advancing antiangiogenesis as an effective cancer therapy and will undoubtedly be evaluated in human clinical trials in the near future.

Original languageEnglish (US)
Article number22
JournalJournal of Translational Medicine
Volume2
DOIs
StatePublished - Jun 25 2004
Externally publishedYes

Fingerprint

Gene transfer
Gene therapy
Genetic Therapy
Angiogenesis Inhibitors
Tumors
Neoplasms
Recombinant Proteins
Genes
Animals
Therapeutics
Animal Models
Clinical Trials
Growth

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Antiangiogenic gene therapy of cancer : Recent developments. / Tandle, Anita; Blazer, Dan G.; Libutti, Steven K.

In: Journal of Translational Medicine, Vol. 2, 22, 25.06.2004.

Research output: Contribution to journalArticle

Tandle, Anita ; Blazer, Dan G. ; Libutti, Steven K. / Antiangiogenic gene therapy of cancer : Recent developments. In: Journal of Translational Medicine. 2004 ; Vol. 2.
@article{32114c93195d434b8fdc30f922373866,
title = "Antiangiogenic gene therapy of cancer: Recent developments",
abstract = "With the role of angiogenesis in tumor growth and progression firmly established, considerable effort has been directed to antiangiogenic therapy as a new modality to treat human cancers. Antiangiogenic agents have recently received much widespread attention but strategies for their optimal use are still being developed. Gene therapy represents an attractive alternative to recombinant protein administration for several reasons. This review evaluates the potential advantages of gene transfer for antiangiogenic cancer therapy and describes preclinical gene transfer work with endogenous angiogenesis inhibitors demonstrating the feasibility of effectively suppressing and even eradicating tumors in animal models. Additionally, we describe the advantages and disadvantages of currently available gene transfer vectors and update novel developments in this field. In conclusion, gene therapy holds great promise in advancing antiangiogenesis as an effective cancer therapy and will undoubtedly be evaluated in human clinical trials in the near future.",
author = "Anita Tandle and Blazer, {Dan G.} and Libutti, {Steven K.}",
year = "2004",
month = "6",
day = "25",
doi = "10.1186/1479-5876-2-22",
language = "English (US)",
volume = "2",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Antiangiogenic gene therapy of cancer

T2 - Recent developments

AU - Tandle, Anita

AU - Blazer, Dan G.

AU - Libutti, Steven K.

PY - 2004/6/25

Y1 - 2004/6/25

N2 - With the role of angiogenesis in tumor growth and progression firmly established, considerable effort has been directed to antiangiogenic therapy as a new modality to treat human cancers. Antiangiogenic agents have recently received much widespread attention but strategies for their optimal use are still being developed. Gene therapy represents an attractive alternative to recombinant protein administration for several reasons. This review evaluates the potential advantages of gene transfer for antiangiogenic cancer therapy and describes preclinical gene transfer work with endogenous angiogenesis inhibitors demonstrating the feasibility of effectively suppressing and even eradicating tumors in animal models. Additionally, we describe the advantages and disadvantages of currently available gene transfer vectors and update novel developments in this field. In conclusion, gene therapy holds great promise in advancing antiangiogenesis as an effective cancer therapy and will undoubtedly be evaluated in human clinical trials in the near future.

AB - With the role of angiogenesis in tumor growth and progression firmly established, considerable effort has been directed to antiangiogenic therapy as a new modality to treat human cancers. Antiangiogenic agents have recently received much widespread attention but strategies for their optimal use are still being developed. Gene therapy represents an attractive alternative to recombinant protein administration for several reasons. This review evaluates the potential advantages of gene transfer for antiangiogenic cancer therapy and describes preclinical gene transfer work with endogenous angiogenesis inhibitors demonstrating the feasibility of effectively suppressing and even eradicating tumors in animal models. Additionally, we describe the advantages and disadvantages of currently available gene transfer vectors and update novel developments in this field. In conclusion, gene therapy holds great promise in advancing antiangiogenesis as an effective cancer therapy and will undoubtedly be evaluated in human clinical trials in the near future.

UR - http://www.scopus.com/inward/record.url?scp=4344625872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344625872&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-2-22

DO - 10.1186/1479-5876-2-22

M3 - Article

VL - 2

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

M1 - 22

ER -